登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002793 股票简称：罗欣药业 公告编号：2025-109 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 2025年12月22日，罗欣药业集团股份有限公司（以下简称"公司"）第五届董事会第三十四次会议在山东 省临沂高新技术产业开发区罗七路管理中心三楼会议室和上海市浦东新区前滩世贸中心会议室以现场表 决和通讯表决相结合的方式召开。会议通知已于2025年12月19日以电话、专人送达、电子邮件等方式发 出。本次会议应出席董事7名，实际出席董事7名，公司董事会秘书列席了会议。公司董事长刘振腾先生 主持了本次会议。会议的召集、召开符合《中华人民共和国公司法》等法律法规、规范性文件和《罗欣 药业集团股份有限公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于转让控股子公司股权的议案》 公司同意下属子公司山东罗欣药业集团股份有限公司（以下简称"山东罗欣"）拟将其持有的控股子公司 罗欣安若维他药业（成都）有限公司（以下简称"罗安公司"）20%股权转让给HELIX HE ...

（文章来源：证券日报） 证券日报网讯 12月23日，罗欣药业发布公告称，公司第五届董事会第三十四次会议审议通过《关于转 让控股子公司股权的议案》。 ...

格隆汇12月23日丨罗欣药业（维权）(002793.SZ)公布，下属子公司山东罗欣药业集团股份有限公司 （简称"山东罗欣"）拟将其持有的罗欣安若维他药业（成都）有限公司（简称"罗安公司"）20%股权以 5,125,000美元转让给 Helix Healthcare B.V.（简称"Helix"）。本次股权转让前，山东罗欣持有罗安公司 70%股权，本次股权转让完成后，山东罗欣持有罗安公司50%股权，罗安公司将不再纳入公司合并报表 范围。 截至本公告披露日，山东罗欣为罗安公司提供的借款余额为2,111.68万元，罗安公司承诺在本次交易完 成前，向山东罗欣清偿2,111.68万元借款，如未在交割前解决可能影响本次交易顺利实施。截至本公告 披露日，公司为罗安公司提供的最高额担保额度为1,500万元，目前担保余额为1,001.11万元，罗安公司 承诺在本次交易完成前，对1,001.11万元银行借款及利息进行清偿或担保方式变更以解除公司的连带担 保责任，如未在交割前解决可能影响本次交易顺利实施。 ...

人民财讯12月23日电，罗欣药业（002793）12月23日公告，下属子公司山东罗欣药业集团股份有限公司 (简称"山东罗欣")拟将其持有的罗欣安若维他药业(成都)有限公司(简称"罗安公司")20%股权以512.5万美 元，转让给Helix Healthcare B.V. 此次股权转让前，山东罗欣持有罗安公司70%股权，转让完成后，山东罗欣持有罗安公司50%股权，罗 安公司将不再纳入公司合并报表范围。转让罗安公司股权有利于公司优化资产和业务结构。 ...

（记者 曾健辉） 截至发稿，罗欣药业市值为54亿元。 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 每经AI快讯，罗欣药业（SZ 002793，收盘价：4.94元）12月23日晚间发布公告称，罗欣药业集团股份 有限公司下属子公司山东罗欣药业集团股份有限公司拟将其持有的罗欣安若维他药业（成都）有限公司 20%股权以约512万美元转让给Helix Healthcare B.V.。本次股权转让前，山东罗欣持有罗安公司70%股 权，本次股权转让完成后，山东罗欣持有罗安公司50%股权，罗安公司将不再纳入公司合并报表范围。 2025年1至6月份，罗欣药业的营业收入构成为：医药工业占比88.11%，医药商业占比10.1%，其他业务 占比1.79%。 ...

3、截至本公告披露日，公司为罗安公司提供的最高额担保额度为 1,500 万 元，目前担保余额为 1,001.11 万元，罗安公司承诺在本次交易完成前，对 1,001.11 万元银行借款及利息进行清偿或担保方式变更以解除公司的连带担保责任，如未 在交割前解决可能影响本次交易顺利实施。 4、后续双方仍需按照协议约定完成款项支付、资产交割等相关手续，最终 能否完成交易尚存在不确定性。 证券代码：002793 股票简称：罗欣药业 公告编号：2025-110 罗欣药业集团股份有限公司 关于转让控股子公司股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、罗欣药业集团股份有限公司（以下简称"公司"、"上市公司"）下属 子公司山东罗欣药业集团股份有限公司（以下简称"山东罗欣"）拟将其持有的 罗欣安若维他药业（成都）有限公司（以下简称"罗安公司"）20%股权以 5,125,000 美元转让给 Helix Healthcare B.V.（以下简称"Helix"）。本次股权转让前，山 东罗欣持有罗安公司 70%股权，本次股权转让完成后，山东罗欣持有罗安公司 ...

罗欣药业集团股份有限公司 第五届董事会第三十四次会议决议公告 证券代码：002793 股票简称：罗欣药业 公告编号：2025-109 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 12 月 22 日，罗欣药业集团股份有限公司（以下简称"公司"）第 五届董事会第三十四次会议在山东省临沂高新技术产业开发区罗七路管理中心 三楼会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结 合的方式召开。会议通知已于 2025 年 12 月 19 日以电话、专人送达、电子邮件 等方式发出。本次会议应出席董事 7 名，实际出席董事 7 名，公司董事会秘书列 席了会议。公司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中 华人民共和国公司法》等法律法规、规范性文件和《罗欣药业集团股份有限公司 章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于转让控股子公司股权的议案》 公司同意下属子公司山东罗欣药业集团股份有限公司（以下简称"山东罗欣"） 拟将其持有的控股子公司罗欣安若维他药业（成都）有限公司（以下简称 ...

Group 1 - The core point of the article is that Luoxin Pharmaceutical reported its latest total number of shareholders as 39,271 as of December 19, 2025 [2]

Core Viewpoint - The event highlighted the commitment of Lunan Pharmaceutical Group to social welfare and health, showcasing its strategic focus on chemical, traditional Chinese, and biopharmaceuticals while promoting regional industrial upgrades [1] Group 1: Event Overview - The Linyi Modern Pharmaceutical Industry High-Quality Development Matchmaking Conference was held on December 19, featuring over 140 enterprises and nearly 1,000 attendees from various sectors including pharmaceuticals, medical devices, and health products [1] - Lunan Pharmaceutical has been rooted in Linyi for 58 years, emphasizing its mission to benefit society and improve quality of life [1] Group 2: Company Strategy and Products - Lunan Pharmaceutical showcased its product strategy focusing on maintaining advantages in chemical pharmaceuticals, significantly developing traditional Chinese medicine, and strengthening biopharmaceuticals [1] - The company presented successful products such as Qidali Jingfang Granules, reflecting its comprehensive strength and innovative vitality in the health sector [1] Group 3: Support and Collaboration - The event featured a policy consultation area where local government departments provided one-stop services to support enterprises in policy applications and resource connections [1] - Representatives from 10 companies, including Lunan Pharmaceutical and others, delivered promotional speeches, indicating a collaborative effort to enhance the pharmaceutical industry [1]

Group 1: Manufacturing Champions Recognition - Shandong Province's Industrial and Information Technology Department has announced the ninth batch of proposed manufacturing champions, with two companies from Linyi's Luozhuang District, including Luoxin Pharmaceutical and Lixin Aluminum, successfully recognized [1] - Luozhuang District has now cultivated a total of 1 national-level and 10 provincial-level manufacturing champions, creating a "1+10" champion enterprise matrix to enhance the region's manufacturing capabilities [1] Group 2: Luoxin Pharmaceutical Innovations - Luoxin Pharmaceutical, a top 100 pharmaceutical company in China, specializes in digestive system diseases and has developed the first domestically produced potassium ion competitive acid blocker, Tegoprazan (brand name: Taixinzan), which has received approval for three indications [4] - The drug is notable for its rapid onset of action within 30 minutes, long-lasting acid suppression, and convenience of use, with all three indications included in the national medical insurance catalog by 2025 [4] - Luoxin has been recognized multiple times for its contributions to the pharmaceutical industry, including national and provincial awards, and has established a comprehensive innovation capability across drug research, production, trade, and healthcare services [4] Group 3: Lixin Aluminum's Green Initiatives - Lixin Aluminum is recognized for its "short-process green industrial chain," achieving over 90% secondary utilization of aluminum resources through its recycling and processing model [8] - The company has an annual production capacity of 100,000 tons, which will increase to 300,000 tons per year after the completion of a new green recycled aluminum alloy project in 2024, with expected annual sales revenue of 2.5 billion yuan [8] - Lixin holds 14 national invention patents and 42 utility model patents, and has established multiple research and development platforms in collaboration with universities, achieving some technologies at an internationally advanced level [8] Group 4: Policy Support and Development Strategies - The Luozhuang District's Industrial and Information Technology Bureau aims to strengthen the cultivation mechanism for manufacturing champions through targeted policy guidance and financial support [9] - The district encourages companies to overcome critical technological challenges and promotes the transformation of scientific achievements [9] - The focus is on building a collaborative industrial community that integrates leading enterprises with small and medium-sized suppliers, leveraging the innovations of Luoxin and Lixin to elevate the entire industrial chain [9]